Floatz logo

gb221

HER2 Positive Breast Carcinoma

Genor Biopharma Co., Ltd.monoclonal_antibodyPhase 3Dormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

176 Active assets in the HER2 Positive Breast Carcinoma cohort.

Asset / SponsorPhaseRating
Trastuzumab
SWOG Cancer Research Network
Phase 4BB
Pertuzumab
SWOG Cancer Research Network
Phase 4BB
Ribociclib
Danish Breast Cancer Cooperative Group
Phase 3BB
Vinorelbine Ditartrate
Fudan University
Phase 3BB
Docetaxel
Ohio State University Comprehensive Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

gb221 is also rated in:

spinal muscular atrophy, type 1Active
CCC
Indicative · Phase 1/2
48 / 100
View asset →
breast cancerDormant
C
Indicative · Phase 1
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →